Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

NCT02996448 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

NIH

Sponsor class

Stopped Safety concerns led to early termination.

Conditions

Autosomal-dominant Hyper-IgE Syndrome

Interventions

DRUG: NDV-3A

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)